JP2022535108A5 - - Google Patents

Info

Publication number
JP2022535108A5
JP2022535108A5 JP2021571941A JP2021571941A JP2022535108A5 JP 2022535108 A5 JP2022535108 A5 JP 2022535108A5 JP 2021571941 A JP2021571941 A JP 2021571941A JP 2021571941 A JP2021571941 A JP 2021571941A JP 2022535108 A5 JP2022535108 A5 JP 2022535108A5
Authority
JP
Japan
Prior art keywords
alkyl
cyclopropane
dicarboxamide
oxyphenyl
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535108A (ja
JP7820152B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035808 external-priority patent/WO2020247418A1/en
Publication of JP2022535108A publication Critical patent/JP2022535108A/ja
Publication of JP2022535108A5 publication Critical patent/JP2022535108A5/ja
Application granted granted Critical
Publication of JP7820152B2 publication Critical patent/JP7820152B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571941A 2019-06-04 2020-06-03 キナーゼ依存性障害の処置のための化合物 Active JP7820152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856920P 2019-06-04 2019-06-04
US62/856,920 2019-06-04
PCT/US2020/035808 WO2020247418A1 (en) 2019-06-04 2020-06-03 Compounds for the treatment of kinase-dependent disorders

Publications (3)

Publication Number Publication Date
JP2022535108A JP2022535108A (ja) 2022-08-04
JP2022535108A5 true JP2022535108A5 (cg-RX-API-DMAC7.html) 2023-06-12
JP7820152B2 JP7820152B2 (ja) 2026-02-25

Family

ID=71842789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571941A Active JP7820152B2 (ja) 2019-06-04 2020-06-03 キナーゼ依存性障害の処置のための化合物

Country Status (10)

Country Link
US (1) US12503438B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980404A1 (cg-RX-API-DMAC7.html)
JP (1) JP7820152B2 (cg-RX-API-DMAC7.html)
CN (1) CN114040912B (cg-RX-API-DMAC7.html)
AR (1) AR119069A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020289324B2 (cg-RX-API-DMAC7.html)
CA (1) CA3139156A1 (cg-RX-API-DMAC7.html)
MA (1) MA56114A (cg-RX-API-DMAC7.html)
TW (1) TWI850394B (cg-RX-API-DMAC7.html)
WO (1) WO2020247418A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
CN114573553B (zh) * 2022-01-27 2023-11-10 广州六顺生物科技有限公司 杂芳环类衍生物及其制备方法和应用
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用
CN116271008A (zh) * 2022-12-30 2023-06-23 广东天普生化医药股份有限公司 含有安柯瑞和卡瑞利珠单抗的药物组合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US8003662B2 (en) 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
JP6696908B2 (ja) * 2014-04-25 2020-05-20 エグゼリクシス, インコーポレイテッド 肺腺癌の治療方法
CN104817497B (zh) * 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
CN110437145A (zh) * 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
SG11202005719UA (en) * 2017-12-20 2020-07-29 Angex Pharmaceutical Inc Carbamate and urea compounds as multikinase inhibitors
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2013523884A5 (cg-RX-API-DMAC7.html)
JP6549703B2 (ja) 新規化合物
CN114945571B (zh) 环状化合物及其使用方法
CA2515197A1 (en) Pyrazolopyridine derivates
CN105209464B (zh) P2x7调节剂
JP2016519096A5 (cg-RX-API-DMAC7.html)
CN115594680A (zh) 一种tead抑制剂
JP2021501220A5 (cg-RX-API-DMAC7.html)
JP2016514719A5 (cg-RX-API-DMAC7.html)
JP2021515036A5 (cg-RX-API-DMAC7.html)
JP2016514718A5 (cg-RX-API-DMAC7.html)
RU2017112518A (ru) Пиридоновые и азапиридоновые соединения и способы применения
JP2017530960A5 (cg-RX-API-DMAC7.html)
JP2012525395A5 (cg-RX-API-DMAC7.html)
KR20190046921A (ko) 세포 대사 과정의 억제제
RU2012136643A (ru) [5,6]- гетероциклическое соединение
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
JP2022551422A5 (cg-RX-API-DMAC7.html)
JP2007504148A5 (cg-RX-API-DMAC7.html)
KR102071095B1 (ko) 지질 합성의 헤테로사이클릭 조절인자
JP2014506589A (ja) 神経障害治療のためのイミダゾ[5,1−f][1,2,4]トリアジン
JP2011509937A5 (cg-RX-API-DMAC7.html)
JP2011529959A5 (cg-RX-API-DMAC7.html)
JP2022017461A5 (cg-RX-API-DMAC7.html)
RU2019116251A (ru) Пиразоло[3,4-b]пиридины и имидазо[1,5-b]пиридазины в качестве ингибиторов pde1